Abstract: Endothelial cells lining the vessel wall control important aspects of vascular homeostasis. In particular, the production of endothelium-derived nitric oxide and activation of soluble guanylate cyclase promotes endothelial quiescence and governs vasomotor function and proportional remodeling of blood vessels. Here, we discuss novel approaches to improve endothelial nitric oxide generation and preserve its bioavailability. We also discuss therapeutic opportunities aimed at activation of soluble guanylate cyclase for multiple cardiovascular indications. (Circ Res.
T he endothelium is the innermost layer of all blood vessels in the body and forms a barrier between the bloodstream and the surrounding tissues. The endothelium in adults is composed of about 2 trillion endothelial cells (ECs), forming a surface of 400 m 2 (≈4300 sq. ft. or 1 / 13 of a football field) and weights about 1.5 kg, 1 which equals the weight of a healthy liver, 2 typically regarded as the biggest organ of the human body. Although blood vessels were described and characterized by Galen, Andreas Vesalius, and William Harvey, the Swiss anatomist William His introduced the term endothelium in 1865. 3 It took another century before the endothelium gained the reputation of being more than just a cellophane wrapper. 4, 5 Although many investigators contributed to this idea of an active endothelium, classic morphology studies by Florey 4 and Weibel and Palade 6 defining unique structures and properties of endothelium by electron microscopy implied an active, secretory role for the endothelium. This study was bolstered by biological experiments by Sir John R. Vane, defining the metabolic role of the endothelium led by the discovery of angiotensin I conversion to angiotensin II by angiotensin-converting enzyme localized on lung endothelium and the identification of the endothelial-derived vasoactive lipid mediator, prostacyclin. 7 After the discovery of biologically active substances produced by the endothelium, the serendipitous discovery of endothelium-derived relaxing factor by Robert F. Furchgott 8 arguably defined one of the most important physiological regulators of blood flow and vascular remodeling. Many outstanding books and review articles exist, highlighting the importance of the endothelium as a central regulator of many cellular processes; however, the purpose of this review is to highlight recent advances and therapeutic opportunities in the nitric oxide (NO)-cGMP pathway.
NO and NO-Sensitive Soluble Guanylate Cyclase
NO is produced by 3 isoforms of NO synthase (NOS): neuronal NO synthase, inducible NOS, and endothelial NOS (eNOS/NOS3). This review focuses on eNOS-derived NO activation of sGC being one of the most important regulatory systems in the body. Although eNOS was originally thought to be a constitutively active enzyme, extensive research in the past 2 decades has proven it to be a highly regulated enzyme that rapidly responds to physiological input. The activity of eNOS is modulated by calcium/calmodulin, 9 post-translational modifications (eg, phosphorylation through Akt1 10, 11 ), protein-protein interactions (eg, caveolin-1 [CAV1] 12 or heat shock protein 90 13 ), and other assorted regulators. 14 NO production is stimulated by various vasoactive factors including catecholamines, 15 bradykinin, 16 and serotonin, 17 as well as physical factors such as fluid shear stress. 18 At physiological levels, NO can buffer reactive oxygen species (ROS) and its lipophilic character allows it to freely permeate membranes to reach circulating cells in the lumen such as neutrophils and platelets and traverse abluminally into the professional contractile cells of blood vessels and vascular smooth muscles cells. In vascular smooth muscles cell, NO activates its main receptor, the NO-sensitive guanylate cyclase (NOsGC), 19 which generates the second messenger cGMP. Three types of cGMP-binding proteins transduce the cellular response of the NO-NOsGC-cGMP pathway (Figure 1 )-cGMP-modulated (cyclic nucleotide-gated) cation channels, cGMP-dependent protein kinases, and cGMP-regulated phosphodiesterases. 20 One of the best studied cGMP-modulated cation channels is the cGMP-gated sodium channel involved in phototransduction in the retina. Light causes a conformational change of opsins, a class of G-protein-coupled receptors, which leads the activation of cGMP-specific phosphodiesterase 6 resulting in a decrease of cGMP-levels and subsequently closing of the sodium channel, causing the cell to hyperpolarize. 21 Cross talk between cGMP and cAMP signaling is achieved through cGMP-regulated phosphodiesterases. Phosphodiesterase 2 and phosphodiesterase 3 are stimulated or inhibited by cGMP, respectively. 22 One of the most important actions of cGMP for the cardiovascular system is the cGMP-dependent activation of cGMP-dependent protein kinase I, which leads to a relaxation of smooth cells through various pathways. 23 NO also acts in cGMP-independent manners (eg, nitrosylation), which will not be discussed here, and the interested reader is referred to several recent reviews.
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Endothelial Dysfunction and NO donors
The NO-NOsGC-cGMP pathway is known to be perturbed in multiple cardiovascular disease states including diabetes mellitus, heart failure (HF), atherosclerosis, and hypertension, and one aspect of endothelial dysfunction is caused by altered bioavailability of eNOS-derived NO. 28 Indeed, under conditions of impaired NO bioavailability either the production of NO by the endothelium or vascular smooth muscles cell responsiveness to NO can be affected by ROS, oxidation of the critical cofactor for eNOS, tetrahydrobiopterin, higher circulating levels of the endogenous inhibitor, asymmetrical dimethylarginine, or upregulation of cGMP degrading phosphodiesterases. 29 If impaired NO production is the source of dysfunction, the logic of prescribing the NO donor nitroglycerin is rationale to improve blood flow in patients with angina pectoris or to reduce preload and afterload in patients with HF. NO donors used in the United States to treat angina pectoris are nitroglycerin, isosorbide dinitrate, isosorbide-5-mononitrate, and amyl nitrite. Isosorbide dinitrate and isosorbide-5-mononitrate are thought to be bioactivated through multiple pathways (eg, cytochrome P450 enzymes), whereas the bioactivation of nitroglycerin is mediated by aldehyde dehydrogenase 2. 30 A caveat of the longterm treatment with NO donors is that they lose their efficacy rapidly (nitrate tolerance) and worsen endothelial dysfunction over time. The nitrate tolerance was already described in 1888 31 and modern-day studies revealed molecular details explaining the effect loss of organic nitrates and their detrimental effect on the endothelium after prolonged administration. Organic nitrates desensitize NOsGC, 32 increase the activity of phosphodiesterases, 33 lead to ROS production (especially the radical superoxide anion [O 2 -• ]), 34 and sensitize the vasculature to vasoconstrictors. 35 In addition to nitroglycerin derivatives, NO gas (INOmax) is administered by inhalation and is approved for the treatment of neonatal respiratory failure, perinatal hypoxia, and pediatric pulmonary hypertension.
Although it seems to be favorable to activate the NO-NOsGC-cGMP pathway most upstream by increasing the pool of NO, the clinical benefit of nitroglycerin-type NO donors is limited likely because of the nonspecific nature of where and when the NO is released justifying the search for other approaches to release endogenous NO or permit activation of the NO-sGC-cGMP pathway in a predictable and sustained manner. [36] [37] [38] CAV1 is the main coat protein of caveolae in ECs and is essential for the formation of caveolae.
39 CAV1-knockout mice lack caveolae and are viable and fertile but show several cardiovascular and pulmonary phenotypes. The knockout mice exhibit impaired mechanosignaling and remodeling, myocardial hypertrophy, metabolic imbalances, pulmonary fibrosis, and hypertension and display elevated plasma lipids, while been protected from atherosclerosis. [40] [41] [42] [43] [44] [45] Endothelial NOS (eNOS) is post-translationally palmitoylated and trafficked to caveolae, 46 where its activity is decreased because of the binding to CAV1. 13, 47 In addition to caveolae-targeted eNOS, a portion of eNOS is localized on the Golgi complex in the absence of CAV1 and can respond to agonists that mobilize calcium. 48, 49 NO derived from eNOS in the vascular system is a major regulator of vascular tone and blood pressure. Domain mapping studies revealed the amino acids 82 to 101 of CAV1 are critical for CAV1 interacting with eNOS 13, 47 (caveolin scaffolding domain), whereas the amino acids T90, T91, and in particular F92 play a crucial role in the inhibitory action of this binding ( Figure 2A ). After activation, eNOS is thought to be released from the inhibitory clamp of CAV1 and phosphorylated by kinases including Akt. 50 Heat shock protein 90 and calmodulin binding lead to a fully activated eNOS, 51 resulting in increased NO release. The eNOS inhibitor cavtratin 52 is composed of the caveolin scaffolding domain fused with a cell-permeable peptide from antennapedia peptide (penetratin) to allow cavtratin to pass the plasma membrane. Cavtratin decreases eNOS activity by mimicking the CAV1 inhibitory clamp ( Figure 2B ) and does not affect the function of other NOSs in vivo and targets eNOS to a significant extent. 53 Cavtratin reduces microvascular hyperpermeability and blocks tumor progression, 52, 54 restores tight junctions in C-C motif chemokine 2-treated brain microvascular ECs, 55 inhibits matrix metalloproteinase-2/9 and cyclooxygenase-2, which could lead to stabilization of atherosclerotic plaques and protective effects for intracerebral hemorrhages. 56, 57 Cavtratin also diminishes glia cell growth 58 and protects the blood-brain barrier when treated with vascular endothelial growth factor A in a mouse model of multiple sclerosis. 59 Whether eNOS is the sole target of cavtrain is not known; however, a majority of the effects of cavtratin in blocking vascular endothelial growth factorstimulated vascular leakage and tumor growth is eliminated when experiments were conducted in eNOS-deficient mice. 52 It is feasible that cavtratin could increase blood pressure when administered chronically; however, there are no data supporting this potential side effect. Mechanistically, we suggest that cavtratin preferentially targets eNOS in caveolae not eNOS on the Golgi, therefore, exhibiting a different pharmacological profile than chemical inhibitors of eNOS. Alternatively, it is possible that high enough doses of cavtratin have not been given to elicit a hemodynamic effect. In addition, because CAV1 is thought to regulate many intracellular signaling pathways, cavtratin may exert pleiotropic actions in multiple tissues especially those lacking eNOS.
Taking advantage of detailed structure-function studies of the CAV1/eNOS interaction, mutation of key residues in CAV1 responsible for inhibition of eNOS function resulted in the identification of a cell-permeable peptide that activates eNOS, called cavnoxin 60 ( Figure 2C ). Cavnoxin is a synthetic 20 amino acid peptide of the caveolin scaffolding domain with a triple alanine substitution for T90, T91, and F92 fused with antennapedia peptide (penetratin) to promote cell entry. 61 Cavnoxin increases NO levels, reduces vascular tone, and lowers the mean blood pressure in wild-type mice, an effect lost in either eNOS-knockout or CAV1-knockout animals, suggesting specificity for the inhibitory clamp of CAV1. 60 Chronic cavnoxin administration reduces atherosclerosis in ApoE-knockout mice fed a Western diet and in diabetic, atherosclerotic mice, 62 and again the loss of eNOS genetically attenuates the actions of cavnoxin. These 2 studies imply that cavnoxin can reduce the inhibitory effect of caveolin on eNOS function, allowing for enhancement of endogenous NO biosynthesis. Recent genetic data using an endothelial-specific transgenic mouse expressing F92A CAV1 document that regulated expression of the transgene is sufficient to increase NO bioavailability, resulting in a significantly lower systolic blood pressure. 63 Future work examining the spectrum of actions of cavtratin in a variety of models will yield insight into whether this strategy will improve endothelial dysfunction and reduce disease progression.
Disruption of eNOS-Hemoglobin α Interactions to Improve NO Bioavailability
There is evidence that the release of eNOS-derived NO and the downstream actions of NO are not always stoichiometric, raising the idea that perhaps the release of NO from the endothelium to smooth muscle could be quenched by an endogenous inhibitory molecule. Indeed, ECs express the α subunit of hemoglobin, which forms a macromolecular complex with eNOS and controls the flux of bioavailable NO in the microcirculaltion. 64 NO binds rapidly and with high affinity to the reduced Fe 2+ -form of hemoglobin α thereby generating nitrate and the resultant oxidized Fe 3+ hemoglobin α. The Fe 3+ hemoglobin α has a much lower affinity for NO, thereby permitting the diffusion of NO generated from eNOS in the endothelium to underlying vascular smooth muscles cell. 65 The enzyme nicotinamide adenine dinucleotide (NADH)-cytochrome b 5 64, 66 Hemoglobin α X increases NO signaling in isolated vessels and decreases systemic blood pressure in mice, 66 reduces systolic blood pressure in angiopoietin-II-induced hypertension in mice, and dilates constricted arterioles isolated from hypertensive patients.
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NOS Transcription Enhancers
AVE3085 and AVE9488 are 2 small molecules that have been identified through a high-throughput screen capable of enhancing the transcription of eNOS 67 in vitro and in vivo. Promoter analysis by luciferase assays revealed that both compounds bind even the shortest fragment of the eNOS promoter (263 bp) but do not overlap with the known eNOS transcription factors (GATA, Sp1/3-like, Elf-1, YY1, Sp1, or PEA3) and even the knockdown of Sp1 does not alter eNOS transcription induced through both compounds. 67 These NOS enhancers have also been shown to enhance vascular tetrahydrobiopterin levels, reduce cuff-induced neointima formation, and augment atherosclerotic plaques in ApoE-knockout animals after Western diet treatment for 12 weeks. 67 AVE9488 promotes beneficial remodeling in a myocardial infarction model, 68 which might be explained through reduced SMAD signaling. 69 
eNOS Recouplers
It is known that eNOS can become uncoupled if exposed to an excess of ROS in conditions such as hypercholesterolemia, hypertension, or diabetes mellitus. The NOS cofactor tetrahydrobiopterin is oxidized by ROS to dihydrobiopterin that renders the enzyme incapable of producing NO but leads to the NADPH-dependent reduction of oxygen to superoxide anion (O 2 -• ). Tetrahydrobiopterin is Food and Drug Administration (FDA) approved for the treatment of phenylketonuria as tetrahydrobiopterin serves as a cofactor for phenylalanine hydroxylase. Tetrahydrobiopterin has been shown to improve endothelial dysfunction in patients having diabetes mellitus and recipients of heart transplants treated with cyclosporine A. 70, 71 However, a clinical study (OXBIO Study) aiming to investigate the pharmacokinetics and the vascular functions of tetrahydrobiopterin in humans 72 could not show any beneficial effect of tetrahydrobiopterin treatment. Oral supplementation with tetrahydrobiopterin leads to significant augmented tetrahydrobiopterin levels in plasma and in some vessel beds, but at the same time, an increased oxidation of tetrahydrobiopterin to dihydrobiopterin was observed, counteracting the beneficial effects of tetrahydrobiopterin supplementation. The authors conclude that other strategies should be developed to target tetrahydrobiopterin-dependent endothelial dysfunction.
NOsGC Stimulators and Activators
NO-Sensitive Guanylate Cyclase
NOsGC is the main physiological receptor for NO and a central element of the signaling pathway from NO to cGMP. NOsGC is a heterodimeric enzyme formed by dimerization of an α 1 -or α 2 -subunit with the heme b containing β 1 -subunit. 73 The α 1 /β 1 isoform is ubiquitously expressed but highly enriched in the lung, brain, and platelets, whereas the α 2 /β 1 -isoform is enriched in the brain, lung, gut, heart, spleen, uterus, and placenta 74 but has been identified in all tissue except platelets. The α 2 /β 1 -isoform is membrane localized in most tissues, which allows it to detect the NO derived from NOS-expressing cells immediately after NO permeating biological membranes. 75 Therefore, the α 2 /β 1 -isoform seems to be the more important isoform and the cytosolic α 1 /β 1 -isoform can be considered rather as a spare receptor. [75] [76] [77] The unstable character of the ligand NO (t 1⁄2 =200 ms 78 ) could explain the evolutionary need for a backup receptor.
Mice deficient in either the α 1 -or α 2 -subunit are viable, fertile, and show normal life expectancies. 77 Mice lacking the β 1 subunit, on the contrary, die within the first month after birth because of intestinal dysfunction. 79 Vessels isolated from α 1 -knockout animals are still responsive to NO, but show a 5-fold higher EC 50 and respond to carbachol (analogue of acetylcholine, endothelium-dependent relaxation) with a reduction of 25% compared with wild-type. 80 However, the loss of the α 2 -subunit results in vessel function indistinguishable to wild-type vessels. These findings that a single knockout of either α-subunit can be compensated by the remaining one corroborate the spare receptor concept. In contrast, the lack of the β 1 -subunit leads to a complete loss of NOsGC function as the stability of the α subunits is depending on the formation of the heterodimer. 79 Accordingly, vessels from β 1 -knockout animals respond to neither NO nor carbachol. 79 Therefore, it is not surprising that global β 1 -knockout animals have significantly increased systolic blood pressure (26 mm Hg) 79 and even the smooth muscle-specific deletion phenocopies the increase in systolic blood pressure. 81 Knockout animals lacking the α 1 -, or β 1 -subunit also display perturbed central nervous function. The interested reader is referred to a recent review covering this phenotype in more detail. 
Ciguats: NOsGC Stimulators and Activators
Drugs capable of activating NOsGC NO independently have been developed and with riociguat clinically approved for the treatment of pulmonary hypertension. The discovery of this target of opportunity derives from studies in the early 1980s showing that the iron-free form of heme b, protoporphyrin-IX, can serve as an NO-independent activator of the NOsGC. 83 But because of its severe photosensitizing effect, protoporphyrin-IX was never used as an NOsGC activator in a clinical setting.
In the past 2 decades, drugs have been identified capable of activating NOsGC in an NO-independent fashion without being photosensitizers. In 2009, the World Health Organization, in charge of the international nonproprietary names, include the class of NOsGC modulators in their catalog and developed the suffix -ciguat as a unique identifier for this drug class. Ciguats can be classified into 2 subgroups: (1) NOsGC stimulators, which act through allosteric regulation and (2) NOsGC activators, which mimic the nitrosyl-heme (Figure 3) conformation. To date, only 1 NOsGC stimulator (riociguat) has been approved and studies with the NOsGC activator cinaciguat have shown significant rates of adverse events, mainly hypotension. 84 Because the NOsGC activators act independent of NO, they might lack the specificity provided by spatially regulated eNOS-derived NO as a source of NO to activate the pathway.
NOsGC Stimulators
The first allosteric activator of NOsGC was YC-1 (lificiguat), a benzyl indazol derivative, which was identified during a screen for novel platelet aggregation inhibitors. 85 This drug was the proof of concept that small molecules can activate the NOsGC independently of NO. Although YC-1 alone activates NOsGC by just 2-to 4-fold, it acts synergistically with NO and can lead up to a 200-to 800-fold stimulation of the enzyme. 86 The binding site of YC-1 has not been mapped, but photolabeling studies identify 2 cysteines in the α 1 -subunit (C239 and C244 in human protein) as potential interaction sites for the YC-1 analog BAY 41-2272, 87, 88 whereas another study showed that an amino-terminal truncated α 1 -subunit (∆aa1-aa258) can still be activated by YC-1. 89 One possible explanation could be that YC-1 and BAY 41-2272 bind to different sites of the α 1 -subunit. In contrast to these findings, binding of YC-1 to the amino-terminal region of the β 1 -subunit has been reported. 90 The intriguing finding of YC-1 led multiple groups to optimize the solubility and efficacy of this compound, which lead finally to the development of riociguat (BAY 63-2521; Adempas). Riociguat activates NOsGC 70-fold at therapeutic concentrations, 91 whereas it acts synergistically with physiological concentrations of NO (0.1-600 nmol/L). 92, 93 Riociguat is approved for the treatment of pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension. Riociguat has shown improved exploratory hemodynamic and echocardiographic parameters in a singledose study, 94 and currently patients are being recruited for phase 2 trial to assess the effects of riociguat in pulmonary hypertension and HF (NCT02744339). As riociguate is eliminated within 7 to 12 hours, the drug has to be taken 3 times daily, which may impact patient compliance. Vericiguat, another NOsGC stimulator, shows an optimized pharmacokinetic profile and allows a once daily dosing regimen. 95 More recently, a dose-finding, phase 2 study (SOCRATES-REDUCED) demonstrated that vericiquat dose dependently reduced circulating NT-proBNP (N-terminal pro-B-type natriuretic peptide), a biomarker for HF, in patients with chronic failure and reduced ejection fraction. 96 Although the primary end point changes in NT-proBNP were not significant, secondary analysis of the dose-responsiveness of the biomarker was encouraging. NOsGC stimulators are currently in clinical development for various other diseases (Table 1) .
NOsGC Activators
Through a high-throughput screening program and structural optimization of lead candidates, cinaciguat (BAY 58-2667) was identified as an NOsGC activator in the early 2000s. [97] [98] [99] The EC 50 of cinaciguat is 10 nmol/L, whereas the compound activates NOsGC ≈35-fold. 100 In contrast to the marked synergism of NOsGC stimulators and NO, NO only acts additively with NOsGC activators. 98 Interestingly, the known NOsGC inhibitor ODQ promotes the activity of NOsGC activators significantly. 98 102 making it easier for the NOsGC activators to occupy the heme binding pocket instead. Because even under physiological conditions some fraction of NOsGC is heme free, NOsGC activators will stimulate this fraction of the enzyme. 103 Analogously, it can also be assumed that NOsGC activators will preferentially target the NOsGC in patients having cardiovascular diseases as under these conditions the increased concentrations of ROS oxidizing the heme b in NOsGC, making the NOsGC more prone to lose its cofactor. 104 A recent study has generated mice lacking the prosthetic heme group of sGC, and these mice are nonresponsive to NO, are hypertensive, and are restored to normal blood pressure with cinaciguat but not the sGC stimulator, BAY 105 proving the pathological significance of Apo-sGC and specificity of cinaciguat. Cinaciguat has been studied in a randomized controlled, phase IIb study (COMPOSE) in patients with acute HF. Treated patients had a marked reduction in blood pressure without any improvement of dyspnea or cardiac index. 106 In an additional study in patients with acute decompensated failure, cinaciguat reduced pulmonary and systemic resistances and blood pressure. 84 Other NOsGC activators are currently in clinical development for various other diseases.
Phosphodiesterase Inhibitors
Phosphodiesterase enzymes were identified in the early 1970s 107 and inhibit the NO-NOsGC-cGMP signaling axis by hydrolyzing the phosphodiester bond of cGMP (or cAMP). We will focus on phosphodiesterase inhibitors affecting cGMP; however, cAMP=modulating phosphodiesterase inhibitors are clinically used for a variety of diseases such as dypridamole (eg, Persantine) as an antiplatelet agent or roflumilast (Daliresp) as an anti-inflammatory drug for bronchitis and chronic obstructive pulmonary disease.
Only a small number of cGMP-specific phosphodiesterase inhibitors are used clinically to date. The best-known indication for this class of phosphodiesterase inhibitors is erectile dysfunction and with sildenafil (Viagra), vardenafil (Levitra), tadalafil (Cialis), and avanafil (Stendra) being the 4 phosphodiesterase 5 inhibitors on the market. Sildenafil (Revatio) and tadalafil (Adcirca) are also used for pulmonary arterial hypertension, and tadalafil (Cialis) has gained FDA approval The clinical targeted PDEs are highlighted in yellow. The brackets indicate the number of isoforms each PDE has. The addressed diseases are listed in italics. BPH indicates benign prostatic hyperplasia; COPD, chronic obstructive pulmonary disorder; ED, erectile dysfunction; HF, heart failure; IC, intermittent claudication; PAH, pulmonary arterial hypertension; and PDE, phosphodiesterase.
for the treatment of benign prostatic hyperplasia. These agents work by inhibiting cGMP breakdown, thereby activating downstream pathways. However, it is surprising that only a small number of phosphodiesterase inhibitors have been developed despite the recognized therapeutic potential of this drug class. 108 Current and ongoing research has revealed that cGMP can be spatially restricted and concentrated in certain subcellular compartments, which may be dysregulated in various diseases such as asthma, inflammation, hypertension, and cardiac arrhythmias. 108 If the mechanistic basis of compartmentalization is targetable, this may lead to the development of additional phosphodiesterase inhibitors. 109, 110 Conclusions NO coupling to NOsGC to generate cGMP is an important regulator of vascular function. Advances in the detailed mechanisms of how NO generation by endothelium is controlled may lead to new opportunities to precisely control the synthesis and bioactivity of endogenous NO. This seems critical because NO is produced locally by the endothelium is triggered by vascular shear stress, axial stretch, and strain imposed by the cardiac cycle, an effect difficult to mimic using chemical approaches. In addition to activating eNOS, improving NO bioavailability and preventing eNOS uncoupling are promising strategies. Downstream of eNOS activation, major efforts are aimed at direct activation of NOsGC for pulmonary hypertension and HF. Balancing the therapeutic efficacy with potential unwarranted side effects such as hypotension is critical for this class of drugs. Appreciation of the physiological sophistication of the vascular endothelium, the rich clinical history of NO donor drugs such as nitroglycerin and the new, emerging class of NOsGC regulators for cardiovascular disease portends that a deeper understanding of how to harness the eNOS-NOsGC pathway may continue to yield important discoveries.
